5De Gramont A,Figer A,Seymonr M,et al.Leucovorin and fluorouracil with or without oxaliplatin as fist-line treatment in adavanced colorectal cancer.J Clin Oncol,2000,18:2938-2947.
6Maindrault-Goebel F,Louet C,Andre T,et al.Oxliplatin added to the simplified bimonthly leucovorin and fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6).Eur J cancer,1999,35(9):1338.
4Cvitkovic E. A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses [J] . Semin Oncol, 1998, 25 (2, Suppl 5): 1.
5Extra JM, Marty M, Brienza S, et al. Pharmaeokineties and safety profile on oxaliplatin [ J ] . Senin Oncol, 1998, 25 (2, Suppl 5): 13.
6Jin ML, Chen, Q, Cheng FQ, et al. Oxaliplatin (OXA) in combination with LV/5-FU in Chinese patients with advanced gastriccancer (AGC) [ J ] . Proc ASCO, 2002, 21 : 558.
7De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first - line treatment in advanced colorectal cancer. J Clin Oncol, 2000, 18(16) : 2938 - 2947.
8Goldberg RM. et al, Oxaliplatin or CPT - 11 + 5 - Fluouracil/leucovorin or Oxa + CPT - 11 in advanced colorectal cancer. Eficacy ad safety result,From a North American Gastrointestinal Intrgroup Study(9741 ). perspectic in Colorectal Cancer, Fourth Intenational Confernee,2002, abstract # 6.
9Goldstein D, Mitchell P, Michal M, et al. Australian experience ofa modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer, 2005, 92(5): 832- 837.
